<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0"
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main" xml:id="_9jgsTmH">A multicenter clinical trial to assess the efficacy of the digital therapeutics for essential hypertension: Rationale and design of the HERB-DH1 trial</title>
				<funder>
					<orgName type="full">CureApp Inc. CureApp Inc</orgName>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>MD</roleName><forename type="first">Kazuomi</forename><surname>Kario</surname></persName>
							<email>kkario@jichi.ac.jp</email>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Division of Cardiovascular Medicine , Department of Medicine , Jichi Medical University School of Medicine , Tochigi , Japan</note>
								<orgName type="department" key="dep1">Division of Cardiovascular Medicine</orgName>
								<orgName type="department" key="dep2">Department of Medicine</orgName>
								<orgName type="institution">Jichi Medical University School of Medicine</orgName>
								<address>
									<settlement>Tochigi</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Akihiro</forename><surname>Nomura</surname></persName>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> CureApp Institute , Karuizawa , Japan</note>
								<orgName type="institution">CureApp Institute</orgName>
								<address>
									<settlement>Karuizawa</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<note type="raw_affiliation"><label>3</label> Innovative Clinical Research Center , Kanazawa University , Japan</note>
								<orgName type="department">Innovative Clinical Research Center</orgName>
								<orgName type="institution">Kanazawa University</orgName>
								<address>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<note type="raw_affiliation"><label>4</label> Department of Cardiovascular Medicine , Kanazawa University Graduate School of Medical Sciences , Kanazawa , Japan</note>
								<orgName type="department">Department of Cardiovascular Medicine</orgName>
								<orgName type="institution">Kanazawa University Graduate School of Medical Sciences</orgName>
								<address>
									<settlement>Kanazawa</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Noriko</forename><surname>Harada Be</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Division of Cardiovascular Medicine , Department of Medicine , Jichi Medical University School of Medicine , Tochigi , Japan</note>
								<orgName type="department" key="dep1">Division of Cardiovascular Medicine</orgName>
								<orgName type="department" key="dep2">Department of Medicine</orgName>
								<orgName type="institution">Jichi Medical University School of Medicine</orgName>
								<address>
									<settlement>Tochigi</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">|</forename><surname>Tomoyuki Tanigawa</surname></persName>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> CureApp Institute , Karuizawa , Japan</note>
								<orgName type="institution">CureApp Institute</orgName>
								<address>
									<settlement>Karuizawa</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<note type="raw_affiliation"><label>5</label> CureApp, Inc , Tokyo , Japan</note>
								<orgName type="institution">CureApp, Inc</orgName>
								<address>
									<settlement>Tokyo</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD, MPH</roleName><forename type="first">Ryuhei</forename><surname>So</surname></persName>
							<affiliation key="aff4">
								<note type="raw_affiliation"><label>5</label> CureApp, Inc , Tokyo , Japan</note>
								<orgName type="institution">CureApp, Inc</orgName>
								<address>
									<settlement>Tokyo</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">|</forename><surname>Kiyose</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Nakagawa</forename><surname>Mpharm</surname></persName>
							<affiliation key="aff4">
								<note type="raw_affiliation"><label>5</label> CureApp, Inc , Tokyo , Japan</note>
								<orgName type="institution">CureApp, Inc</orgName>
								<address>
									<settlement>Tokyo</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Shin</forename><surname>Suzuki</surname></persName>
							<affiliation key="aff4">
								<note type="raw_affiliation"><label>5</label> CureApp, Inc , Tokyo , Japan</note>
								<orgName type="institution">CureApp, Inc</orgName>
								<address>
									<settlement>Tokyo</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ayako</forename><surname>Okura Ba</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Division of Cardiovascular Medicine , Department of Medicine , Jichi Medical University School of Medicine , Tochigi , Japan</note>
								<orgName type="department" key="dep1">Division of Cardiovascular Medicine</orgName>
								<orgName type="department" key="dep2">Department of Medicine</orgName>
								<orgName type="institution">Jichi Medical University School of Medicine</orgName>
								<address>
									<settlement>Tochigi</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">|</forename><surname>Eisuke</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Hida</forename><surname>Phd</surname></persName>
							<affiliation key="aff5">
								<note type="raw_affiliation"><label>6</label> Department of Biostatistics and Data Science , Osaka University Graduate School of Medicine , Osaka , Japan</note>
								<orgName type="department">Department of Biostatistics and Data Science</orgName>
								<orgName type="institution">Osaka University Graduate School of Medicine</orgName>
								<address>
									<settlement>Osaka</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD, MBA, MPH</roleName><forename type="first">Kohta</forename><surname>Satake</surname></persName>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> CureApp Institute , Karuizawa , Japan</note>
								<orgName type="institution">CureApp Institute</orgName>
								<address>
									<settlement>Karuizawa</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<note type="raw_affiliation"><label>5</label> CureApp, Inc , Tokyo , Japan</note>
								<orgName type="institution">CureApp, Inc</orgName>
								<address>
									<settlement>Tokyo</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<note type="raw_affiliation"><label>7</label> Department of Respiratory Medicine , Japanese Red Cross Medical Center , Tokyo , Japan</note>
								<orgName type="department">Department of Respiratory Medicine</orgName>
								<orgName type="institution">Japanese Red Cross Medical Center</orgName>
								<address>
									<settlement>Tokyo</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff7">
								<note type="raw_affiliation">Division of Cardiovascular Medicine , Department of Medicine , Jichi Medical University School of Medicine , 3311-1 , Yakushiji , Shimotsuke , Tochigi , 329-0498 , Japan.</note>
								<orgName type="department" key="dep1">Division of Cardiovascular Medicine</orgName>
								<orgName type="department" key="dep2">Department of Medicine</orgName>
								<orgName type="institution">Jichi Medical University School of Medicine</orgName>
								<address>
									<addrLine>3311-1 Yakushiji</addrLine>
									<postCode>329-0498</postCode>
									<settlement>Shimotsuke</settlement>
									<region>Tochigi</region>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main" xml:id="_CXaPaMq">A multicenter clinical trial to assess the efficacy of the digital therapeutics for essential hypertension: Rationale and design of the HERB-DH1 trial</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">D4BE4DF2A0CFDFCCE56275497ED6B2CF</idno>
					<idno type="DOI">10.1111/jch.13993</idno>
					<note type="submission">Received: 5 May 2020 | Revised: 26 June 2020 | Accepted: 27 June 2020</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-08-31T12:06+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">a91ee48</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=2, consolidateHeader=2, consolidateFunders=1, includeRawAffiliations=true, includeRawCitations=true, includeRawCopyrights=true, generateTeiIds=true, generateTeiCoordinates=[all], sentenceSegmentation=true, flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_dCrDuuD"><p xml:id="_xXqKuyw"><s xml:id="_qGYetGv">This trial is</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<facsimile>
		<surface n="1" ulx="0.0" uly="0.0" lrx="595.276" lry="782.362"/>
		<surface n="2" ulx="0.0" uly="0.0" lrx="595.276" lry="782.362"/>
		<surface n="3" ulx="0.0" uly="0.0" lrx="595.276" lry="782.362"/>
		<surface n="4" ulx="0.0" uly="0.0" lrx="595.276" lry="782.362"/>
		<surface n="5" ulx="0.0" uly="0.0" lrx="595.276" lry="782.362"/>
		<surface n="6" ulx="0.0" uly="0.0" lrx="595.276" lry="782.362"/>
		<surface n="7" ulx="0.0" uly="0.0" lrx="595.276" lry="782.362"/>
		<surface n="8" ulx="0.0" uly="0.0" lrx="595.276" lry="782.362"/>
		<surface n="9" ulx="0.0" uly="0.0" lrx="595.276" lry="782.362"/>
		<surface n="10" ulx="0.0" uly="0.0" lrx="595.276" lry="782.362"/>
	</facsimile>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1" xml:id="_qGuxp94">| INTRODUC TI ON</head><p xml:id="_ebxnjFP"><s xml:id="_ZZu392H">Hypertension is the most considerable but treatable risk factor of cardiovascular disease (CVD) and is thus an enormous economic and social burden. <ref type="bibr" target="#b0">1</ref> Previous randomized controlled clinical trials using various antihypertensive drugs clearly demonstrated that blood pressure (BP) lowering per se is associated with a reduction of CVD events, independently of the class of antihypertensive drugs. <ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref></s><s xml:id="_MpBDbVk"><ref type="bibr" target="#b3">[4]</ref> Reductions of systolic BP by 10 mmHg and diastolic BP by 5 mmHg have been shown to reduce stroke and heart failure by 25%, and coronary artery disease and total mortality by 15%. <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b2">3,</ref><ref type="bibr" target="#b3">4</ref></s><s xml:id="_JFVdq4G">Both early BP control and lower BP control over 24-hour are essential to achieve "zero" CVD events. <ref type="bibr" target="#b4">5,</ref><ref type="bibr" target="#b5">6</ref></s><s xml:id="_HjZvHfN">spite robust development of various antihypertensive drugs of different classes, and the introduction of community-based lifestyle initiatives as non-pharmacological therapy, real-world BP control rate remains poor. <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b6">7</ref></s><s xml:id="_r7UUAgq">The BP control rate for the threshold of 140/90 mmHg varies widely from 15% to 70% globally. <ref type="bibr" target="#b4">5,</ref><ref type="bibr" target="#b7">8</ref></s><s xml:id="_cjJtjwW">Recently, released guidelines for the management of hypertension lowered the target BP to &lt;130/80 mmHg, and thus, the prevalence of uncontrolled hypertension using the new threshold (130/80 mmHg) has been markedly increased. <ref type="bibr" target="#b6">7</ref></s><s xml:id="_JcFxSZ3"> order to achieve the current targets for BP control, real-world innovations in the interventions for hypertensive management are urgently needed. <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b6">7</ref></s><s xml:id="_vtRCQ5Y">As information and communication technology (ICT) become increasingly central to our daily lives, development of digital health care and medicine has become a "hot" topic. <ref type="bibr" target="#b8">9,</ref><ref type="bibr" target="#b9">10</ref></s><s xml:id="_hRCgBCt">In the era of digital therapeutics (DTx), various trials using applications for chronic conditions such as nicotine dependence, <ref type="bibr" target="#b10">11,</ref><ref type="bibr" target="#b11">12</ref> substance abuse, <ref type="bibr" target="#b12">13</ref> or attention deficit hyperactivity disorder <ref type="bibr" target="#b13">14</ref> have been initiated.</s><s xml:id="_Ew6gHrP">In the case of hypertension management, several non-pharmacological intermittent educational interventions have been well-validated in previous studies.</s><s xml:id="_D6QYMvM">For example, in our previous 3-month intervention study, a face-to-face approach by professional nutritionists reduced salt intake by 1.8 g/per day, resulting in a significant reduction to 7.3 mmHg of the 24-hour ambulatory systolic BP. <ref type="bibr" target="#b14">15</ref> However, non-pharmacological approaches are not consistently successful across all settings, because their efficacy is highly dependent on the characteristics of individual patients.</s></p><p xml:id="_6NywwQr"><s xml:id="_nkuwXNU">DTx is an emerging therapeutic method using software programs such as smartphone apps and/or device algorithms. <ref type="bibr" target="#b15">16</ref></s><s xml:id="_5s5JSGq">Here, we describe our development of a new interactive smartphone app, HERB, to lower BP, based on an algorithm that helps users to make lifestyle modifications in conjunction with medically validated non-pharmacological interventions, such as salt reduction, maintenance of adequate body weight, regular exercise, and alcohol restriction.</s><s xml:id="_YwUzqeK">We incorporated the advance in the field of behavioral science 17 specially adapted for the smartphone app into our antihypertensive program.</s><s xml:id="_6nCwarp">In addition, the application can assess the personalities, behavioral characteristics, and hypertension determinants of individual patients to provide adequate guidance on an individual level.</s></p><p xml:id="_29BSBJA"><s xml:id="_EjwWbRT">To demonstrate the efficacy of this smartphone app for personalized hypertension management, we have initiated a randomized intervention trial.</s><s xml:id="_2XW4rHq">We here present the design and rationale of the HERB-DH1 (HERB digital hypertension 1) trial, which is the first randomized controlled trial (RCT) of digital hypertensive therapeutics.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2" xml:id="_9RyYzge">| ME THODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1" xml:id="_TM6huEP">| Overall trial design</head><p xml:id="_zQVcX4v"><s xml:id="_mf6Mjqp">This is a randomized, controlled, multicenter, open-label trial.</s><s xml:id="_Crh2xm9">We aim to evaluate the efficacy of a smartphone app, HERB Mobile, for the treatment of essential hypertension in addition to guideline-based promotion of lifestyle modification.</s><s xml:id="_Re6VBa9">Patients in the intervention group will be provided the HERB smartphone app, and their primary physicians will be provided a web-based patient management console, HERB Console, for 24 weeks.</s><s xml:id="_sxY8Wxk">Figure <ref type="figure">1</ref> shows the flowchart of this trial, and Table <ref type="table">1</ref> shows the overall follow-up schedule.</s><s xml:id="_uqhby28">This trial will be conducted in compliance with the Declaration of Helsinki, Medical Device Good Clinical Practice, and all other applicable laws and guidelines in Japan.</s><s xml:id="_5rDsmTF">This trial protocol was also approved by the Institutional Review Board at Jinbo Orthopedics (Tokyo), Jichi Medical University Hospital (Tochigi, Japan) and affiliate institutions and was registered at the Japan Registry of Clinical Trials (jRCT2032190148).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2" xml:id="_rZnAaUs">| HERB: Digital therapeutic system for hypertension</head><p xml:id="_jcraF3g"><s xml:id="_YufCrr9">The "HERB" system is investigational software as a medical device (SaMD) that consists of a smartphone app for patients (HERB Mobile), a web application for health care providers (HERB Console), and a data server (Figure <ref type="figure">2</ref>).</s><s xml:id="_2ZrUpBY">The HERB smartphone app was developed at CureApp Inc. under the supervision of the Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine.</s><s xml:id="_DrD59fs">The app runs on both iOS and Android platforms.</s><s xml:id="_EeZYrxT">The app's prescription code is provided to the patients in the intervention group at the timing of randomization via the electric data capture (EDC) system (DATATRAK ONE ® ; DATATRAK International).</s></p><p xml:id="_ByWAVtv"><s xml:id="_Fb4hNwa">Patients download the app through their smartphones, activate the app by entering the prescription code, and input their personal baseline characteristics, including age, sex, lifestyle, social background, and behavior patterns.</s><s xml:id="_ERC2PzW">These data are efficiently gathered through conversations with a virtual nurse in the app.</s></p><p xml:id="_dcHu26p"><s xml:id="_3Q6BUDr">The HERB Mobile will retrieve BP data measured by home BP monitoring (HBPM) via a Bluetooth ® connection.</s><s xml:id="_7v9Drau">The patient data will then be securely transferred to the data server and analyzed based on an algorithm developed with the assistance of health professionals in order to generate a personalized program of lifestyle modifications to lower BP.</s><s xml:id="_muH8ZYk">The patient data, including the BP record, various daily activities, and progress on the proposed program, will be simultaneously shown to health care providers through the HERB Console.</s><s xml:id="_txPdXZA">Based on the personal data, the physicians will support patients to promote daily app usage including watching educational videos in the app etc. and will educate them in regard to BP and its measurement.</s></p><p xml:id="_rfS84dY"><s xml:id="_c88x5Hp">The HERB Mobile has the following 3 stages to ensure the life- Through this process, the app will allow the lifestyle plans devised by users to take root and realize the necessary behavioral changes to reduce BP.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.3" xml:id="_5YkGk9m">| Outcomes</head><p xml:id="_6k4QnYZ"><s xml:id="_8MZBrJH">The primary outcome is the mean change from baseline to 12 weeks in 24-hour systolic BP (SBP) measured by ambulatory BP monitoring (ABPM).</s><s xml:id="_6KPdZFK">We will also evaluate secondary outcomes at 12 and 24 weeks (compared with baseline) as shown in Table <ref type="table">2</ref>. ABPM will be taken at the baseline, at 12 weeks, and at 24 weeks after registration for the primary outcome.</s><s xml:id="_2dX6AgF">In this trial, adverse event is defined as any unfavorable medical occurrences for all participants (both the intervention and control groups).</s><s xml:id="_6dvXCp3">Participants suffering from adverse events may be considered termination from the trial at their physicians' discretion.</s></p><formula xml:id="formula_0">• • • ○ ○ • • Baseline characteristics • Examination Subjective • • • • • • ○ ○ • • Objective • • • • • • ○ ○ • • Physical Height • Weight • • • • ○ ○ • • BMI • • • • ○ ○ • • Waist circumference • • • • Physiological functions</formula><p xml:id="_XnbgsHH"><s xml:id="_dcpRmBK">ABPM • • • • Home BP and HR (awake and bedtime) • • • • ○ ○ • • Office BP and HR • • • • ○ ○ • • 12-lead ECG • Epworth sleepiness scale • Laboratory Blood test • • • • Pregnancy test ○ Urinalysis • • • • Salt intake check sheet • • • • Medication usage • ○ ○ • ○ Concomitant medication &amp; treatment • • • Adverse events</s></p><p xml:id="_5PEyyjk"><s xml:id="_A29P7N6">• • 17517176, 2020, 9, Downloaded from <ref type="url" target="https://onlinelibrary.wiley.com/doi/10.1111/jch.13993">https://onlinelibrary.wiley.com/doi/10.1111/jch.13993</ref>,</s><s xml:id="_9FphNmw">Wiley Online Library on [12/03/2025].</s><s xml:id="_xqvKyHe">See the Terms and Conditions (<ref type="url" target="https://onlinelibrary.wiley.com/terms-and-conditions">https://onlinelibrary.wiley.com/terms-and-conditions</ref>)</s><s xml:id="_4SZrT65">on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.4" xml:id="_MNpmhbZ">| Patient recruitment and randomization</head><p xml:id="_JBtd6Vy"><s xml:id="_K62XFhx">We will recruit patients with essential hypertension from December 2019 to May 2020 or until the recruitment process completes; we plan to follow them until November 2020.</s><s xml:id="_EXBwF2w">Participants who meet all inclusion criteria will be included in the trial (Table <ref type="table">3</ref>) and those meeting any of the exclusion criteria will be excluded from the trial (Table <ref type="table">4</ref>).</s></p><p xml:id="_6Nz6CnK"><s xml:id="_HgsRWSN">We will obtain written informed consent from all the trial participants.</s></p><p xml:id="_gUR3j5N"><s xml:id="_nC6p8n7">We will randomize eligible patients to the intervention group (HERB system + standard lifestyle modification by the doctor) or the control group (standard lifestyle modification alone) using an independent web-based block randomization system, with stratification by centres, history of antihypertensive medications, and 24-hour SBP in ABPM at registration (≥145 mmHg or &lt;145 mmHg).</s><s xml:id="_VMhMkMg">The EDC system will automatically allocate patients to either the intervention or control group.</s></p><p xml:id="_jsAYTx4"><s xml:id="_nDVMqBT">Patients in the intervention group will be instructed to connect the HBPM device to the HERB Mobile via Bluetooth and forward the BP values to the HERB Mobile.</s><s xml:id="_CzERnqx">The patients in the control group will be instructed to connect the HBPM device using specific software available at the study site and provide the data stored in the HBPM device at their planned visit.</s><s xml:id="_RJ2sztT">Both groups will receive instruction on lifestyle modifications as a standard regimen for essential hypertension based on the current recommendations in JSH 2019</s></p><p xml:id="_XG2AwV5"><s xml:id="_frZFwr2">Guideline. <ref type="bibr" target="#b0">1</ref> The principal investigators or sub-investigators will give patients relevant instructions with the help of a brochure on lifestyle modifications.</s><s xml:id="_9xew9DT">At each study visit, patients in both groups will check the progress of lifestyle modification on a specific check sheet, and patients in the intervention group will also discuss with their physicians on what to focus until next clinic visit with reference to their progress of the program.</s></p><p xml:id="_4cv9x5J"><s xml:id="_HGt4h8D">F I G U R E 2 Overview of HERB system.</s><s xml:id="_APXx43U">The HERB system consists of "HERB Mobile" smartphone application for patients and "HERB Console" web-based patient management console F I G U R E 3 App-supported lifestyle modification in HERB Mobile.</s><s xml:id="_XAYxCCu">The HERB Mobile uses a 3-step approach to ensure lifestyle modification: input and education, app-initiated experiments, and self-planning and evaluation.</s><s xml:id="_kmkdZj4">Through this process, the app users can change their behavior to reduce their blood pressure</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.5" xml:id="_Dsxz563">| Follow-up</head><p xml:id="_zp9nK3a"><s xml:id="_3mvxxbK">During the follow-up (Table <ref type="table">1</ref>), the following interventions will be BPs. <ref type="bibr" target="#b17">18,</ref><ref type="bibr" target="#b18">19</ref></s><s xml:id="_s9N68YZ">Antihypertensive or other medications can be used after 12 weeks of randomization according to the JSH 2019 Guideline and the discretion of physicians 1 .</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.6" xml:id="_wVsG5Vx">|</head><p xml:id="_YxT5QaE"><s xml:id="_GMcUb89">Blood pressure measurement 2.6.1 | Ambulatory BP Ambulatory BP will be taken using the validated TM-2441 (A&amp;D Co.) device 20 based on the JSH Guidelines and HOPE Asia Network recommendations for the clinical use of 24-hour ABPM. 21-23</s><s xml:id="_3GMW8ha">In brief, we will first check whether the discrepancy of BPs between office BP and ABPM is equal to or &lt;5 mmHg.</s><s xml:id="_QtUBdzM">The total measurement duration should exceed 25 hours, and the first 1 hours will be removed from the analysis.</s><s xml:id="_TksybUb">The measurement intervals are 30 minutes in both daytime and nighttime.</s><s xml:id="_SDnQ27g">Daytime and nighttime TA B L E 2 Primary and secondary outcomes Primary outcome Mean change in 24-h SBP by ABPM at 12 wk Secondary outcomes [Evaluated at both 12 and 24 wk] 1) Management rate (goal 1, home SBP &lt; 135 mmHg and DBP &lt; 85 mmHg; goal 2, home SBP &lt; 125 mmHg and DBP &lt; 75 mmHg) 2) Efficacy rate (percentage of patients whose mean change in 24-h SBP is equal to or more than 5 mmHg) 3) Mean changes by ABPM in 24-h DBP 4) Daytime/nighttime SBPs and DBPs, 24-h pulse pressure, 24-h/ daytime/nighttime HRs, and 24-h SBPs and DBPs in the extremedipper/dipper/non-dipper/riser groups 5) Coefficient of variations in 24-h/daytime/nighttime SBPs and DBPs 6) Mean changes in home awake and nighttime SBP, DBP, and HR 7) Coefficient of variations in home awake and bedtime SBP and DBP 8) Mean changes in office SBP, DBP, and HR 9) Mean changes in weight, BMI, and waist circumference 10) Mean change in points obtained by salt intake check sheet 11) Changes in each variable by blood tests and urinalysis 12) Smartphone app-related variables (app usage rate, progress of app educational programs, etc.) 13) Rate of home BP measurement, rate of behavior modification, and rate of self-monitoring 14) Any adverse events including device-related adverse events 15) Malfunctions of the investigational medical device [Evaluated at 24 wk] 16) Mean change in 24-h SBP by ABPM at 24 wk 17) Percentage of medication users; mean changes between 12 and 24 wk by ABPM in 24-h/daytime/nighttime SBPs and DBPs 18) Mean changes between 12 and 24 wk in home awake/bedtime SBPs and DBPs Abbreviations: ABPM, ambulatory blood pressure monitoring; BMI, body mass index; DBP, diastolic blood pressure;HP, heart rate; SBP, systolic blood pressure.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_eGmmyMA">TA B L E 3 Inclusion criteria</head><p xml:id="_88pcExc"><s xml:id="_tzqS9ja">We will include patients who meet all the following criteria:</s></p><p xml:id="_69xBXG5"><s xml:id="_cdYQ4Qj">1) Age ≥20 y and &lt;65 y</s></p><p xml:id="_E7pffxd"><s xml:id="_N97T7Jd">2) Diagnosed with essential hypertension (Office SBP 140-179 mmHg, and/or DBP 90-109 mmHg)</s></p><p xml:id="_sbcEwxE"><s xml:id="_djD7vur">3) 24-h mean BP ≥130 mmHg by ABPM at screening 4) Antihypertensive medication-naïve for more than 3 mo before registration 5) Can use a smartphone daily (operating system: Android 6.0 and above or iOS 11.0 or above) 6) Agree to receive ABPM at both 12 and 24 wk after randomization 7) Investigators or clinical trial physicians assesses it is reasonable for the patient to receive 12-wk lifestyle modification without antihypertensive medications Abbreviations: ABPM, ambulatory blood pressure monitoring; DBP, diastolic blood pressure; SBP, systolic blood pressure.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_kWQN6dG">TA B L E 4 Exclusion criteria</head><p xml:id="_VbcasFs"><s xml:id="_QMqfFar">We will exclude patients who meet any of the following criteria: Abbreviations are the same as in Table <ref type="table">3</ref>.</s></p><p xml:id="_gbDccQv"><s xml:id="_wjRJxZw">| 1719</s></p><formula xml:id="formula_1">KARIO et Al.</formula><p xml:id="_SsGx7gH"><s xml:id="_24zYnRv">are defined from the participants' diaries.</s><s xml:id="_9t6cbMK">SBP ≤70 or ≥250, DBP ≤30 or ≥130, and pulse pressure ≤20 or ≥160 will be considered outliers and removed from the analysis.</s><s xml:id="_sWmzxsy">The minimum required rate of measurement will be 70% of successful readings.</s><s xml:id="_gqK58jp">The mean 24-hour BP will be calculated as an arithmetic mean by averaging all successful readings.</s></p><p xml:id="_SwruXWp"><s xml:id="_tYMG4wg">All patients will record the times that they fall asleep or wake up in their diaries.</s><s xml:id="_Npfye7W">All individuals will be instructed to rest or sleep during the nighttime and to maintain their usual activities during the daytime.</s><s xml:id="_3CxMMKe">Nighttime readings will be those ranging from the time of falling asleep to the time of waking up based on the diary entries, and the remaining readings will be defined as daytime readings.</s></p><p xml:id="_PwWxYYs"><s xml:id="_sNbSSQ4">The night/day SBP ratio will be calculated, and the patients will be classified into the following four dipping groups on the basis of the baseline nocturnal BP fall: extreme dippers, with a nocturnal BP fall of 20% or more; dippers, with a fall between 10% and 20%; non-dippers, with a fall between 0% and 10%; and risers, with a nocturnal increase of SBP.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.6.2" xml:id="_6CvJydy">| Home BP</head><p xml:id="_WbYGkJF"><s xml:id="_spZrxZZ">Patients will be instructed to measure their BP at home based on the instructions of the JSH 2019 Guideline 1 and the recommendations of the HOPE Asia Network <ref type="bibr" target="#b23">24,</ref><ref type="bibr" target="#b24">25</ref> using the validated HBPM device (UA-651BLE; A&amp;D Co.) twice in the morning and twice at bedtime for 7 days (or a minimum of 5 days) before the planned study visit.</s></p><p xml:id="_aJXAw5p"><s xml:id="_289cm8t">The morning measurements are taken within 1 hour after waking up, after urination, before taking any medications, prior to eating breakfast, and after resting 1-2 minutes while in a seated position in a quiet room without talking.</s><s xml:id="_mQbtUJJ">The cuff position should be maintained at the heart level.</s><s xml:id="_MtE5hX6">The bedtime measurements are to be taken before going to bed and after 1-2 minutes rest in a seated position.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.6.3" xml:id="_WVMrqzE">| Office BP</head><p xml:id="_tJbFyqu"><s xml:id="_nZfr8NX">Office BPs are measured twice based on the JSH 2019 Guideline, <ref type="bibr" target="#b0">1</ref> and the average of the stable values ( 5 mmHg difference) will be recorded.</s><s xml:id="_jvz3GGj">Office BP measurements are to be taken after resting 1-2 minutes while in a seated position in a quiet room at an appropriate temperature without talking.</s><s xml:id="_3MHSEP6">The center of the cuff is positioned at the heart level.</s><s xml:id="_Mqz4GDM">The interval between the two measurements should be 1-2 minutes.</s><s xml:id="_AMW4WbY">If these BP values differ significantly, additional BP measurements will be taken.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.7" xml:id="_EDamQBD">| Data monitoring</head><p xml:id="_ksQmXVr"><s xml:id="_gX56fxp">On-site data monitoring will be conducted by an independent monitoring staff.</s><s xml:id="_qJcujGp">Moreover, the staff will review the trial database to confirm that the principal investigator and sub-investigators at each institution conducted the clinical trial according to the research protocol and standard operation procedures.</s><s xml:id="_tuEdJ6a">If necessary, data queries will also be made.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.8" xml:id="_EbQrhva">| Statistics</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.8.1" xml:id="_6dKUErB">| Sample size</head><p xml:id="_JPKJyBn"><s xml:id="_AeV7v47">The mean change from baseline to 12 weeks in 24-hour SBP by ABPM is the primary outcome of this trial.</s><s xml:id="_PaREPwR">In our HERB pilot study vention and control groups at 5 mmHg with an SD of 14 mmHg.</s><s xml:id="_6D2tvHX">In the sample size calculation, we determined that the number of patients required per group was 165 at a two-tailed alpha level of 5% and 90% power.</s><s xml:id="_FgQUc54">Assuming a dropout rate of 10%, we will need a total of 180 patients per group for the trial.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.8.2" xml:id="_NUJDcXw">| Statistical analysis</head><p xml:id="_4bRAVEN"><s xml:id="_uKQxEFN">All analysis will be based on the intention-to-treat principle.</s><s xml:id="_krdD73B">The baseline characteristics will be described as the mean and standard deviation, or median and quantiles (for continuous variables), or proportion (for categorical variables).</s><s xml:id="_e8StwkX">We will compare the primary and secondary outcomes between the intervention group and controls.</s></p><p xml:id="_nqBkDEk"><s xml:id="_xvs6KdT">For the analyses, a two-tailed P value less than 0.05 will be considered as statistically significant.</s><s xml:id="_4qeXcuA">We will calculate 95% confidence intervals (CIs).</s><s xml:id="_B59zyRd">Analysis of the primary endpoint will be performed using the analysis of covariance (ANCOVA) including centers, history of antihypertensive medications, and 24-hour SBP in ABPM at registration.</s><s xml:id="_3Vcnuv3">Moreover, we will compare secondary outcomes between the groups at each defined period using ANCOVA, or logistic regression adjusted by appropriate covariates.</s><s xml:id="_yNfGXHR">In addition, we will perform a sensitivity analysis based on the Per-Protocol Set for these analyses.</s><s xml:id="_kjYK89e">A statistical analysis plan will be completed prior to locking the database.</s><s xml:id="_mtEA37s">SAS statistical software version 9.4 or higher (SAS Institute Inc.) will be used for the analyses.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3" xml:id="_h3g67Cs">| D ISCUSS I ON</head><p xml:id="_rdyj4rf"><s xml:id="_27FRZdU">The</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1" xml:id="_uX2CtWv">| Primary outcome</head><p xml:id="_qJFb2Dv"><s xml:id="_yPKdMrr">The primary outcome of the HERB-DH1 trial is the reduction of 24-hour SBP measured by ABPM at 12 weeks.</s><s xml:id="_kUHcYRj">Recently, released guidelines or recommendations for the management of hypertension have recommended the use of out-of-office BP evaluated by ABPM and/or home BP monitoring. <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b4">5,</ref><ref type="bibr" target="#b6">7,</ref><ref type="bibr" target="#b22">23,</ref><ref type="bibr" target="#b25">26,</ref><ref type="bibr" target="#b26">27</ref></s><s xml:id="_UucsvxT">This is because all the previous population-based and clinical studies clearly demonstrated that out-of-office BP was more closely associated with organ damages and CVD prognosis than office BP. <ref type="bibr" target="#b27">28</ref></s><s xml:id="_DhVZKaR">ABPM, which can monitor BP through the day, in particular allows for an increased number of objective measurements.</s><s xml:id="_4qa4yrn">Thus, all the recent clinical trials of nonpharmacological devices for hypertension treatment have assigned the mean change in 24-hour SBP measured by ABPM as the primary outcome. <ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b29">30</ref></s><s xml:id="_Vpqq7q6">A reduction of 5 mmHg or more of 24-hour SBP will support the evidence of a reduction of CVD events by 20%. 31</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2" xml:id="_UTPMV7X">| Validated non-pharmacological interventions of HERB</head><p xml:id="_XFtEt4T"><s xml:id="_72wbRKE">HERB Mobile targets multiple lifestyle modification components, such as reduction of salt intake, body weight control, exercise, sleep conditions, stress management, and cessation of smoking and drinking alcohol (Figure 2).</s><s xml:id="_4YUxtzz">Antihypertensive effects of several lifestyle modifications have been shown in meta-analyses, for example, reducing salt intake by 4.6 g/d lowered SBP/DBP by 4.96 ± 0.40/2.73</s><s xml:id="_qCJMYA9">± 0.24 mmHg 32 , reducing body weight by 4.0 kg in 6 months contributed to SBP/DBP reduction of 4.5/3.2</s><s xml:id="_4BnzRzB">mmHg, 33 30-60 minutes/d of exercise reduced SBP/DBP by 4.6/2.4</s><s xml:id="_9vgK9Sp">mmHg, 34 and reducing alcohol intake by 76% lowered SBP/DBP by 3.31/2.04</s><s xml:id="_zkvRPEz">mmHg. 35</s><s xml:id="_59cd9jA">Sleep conditions, especially short sleep duration and psychological stress, are also associated with the development of hypertension. 36,37</s><s xml:id="_WV4TRfm">HERB Mobile will provide guidance based on a combination of several components of intervention to maximize the potential BP-lowering effect, since the outcome from multiple components is better than that from a single component.</s><s xml:id="_BbzEBhC">The JSH2019 Guideline mentioned the synergistic effects of multiple components of intervention: the DASH (Dietary Approach for Stop Hypertension) diet, DASH diet plus reduction of salt intake, 38 and body weight control plus reduction of salt intake, 39 indicated to potentiate the effect of BP-lowering.</s><s xml:id="_RPZUR5R">dividual patients.</s><s xml:id="_Cu3QF2Y">On the other hand, this app will take a personalized approach to assess the personal data and provide suitable directions for each individuals; thus, the BP-lowering effect of this app may be sustainable for a longer period of time than other standard nonpharmacological interventions.</s><s xml:id="_z88RPWn">This smartphone app will enable us to introduce personalized medicine into the clinical practice of BP management.</s><s xml:id="_ehqqbvu">If the influencing factors of each component and "the responders," which are characterized specific sensitivity of each intervention, are revealed, we will finally be able to categorize hypertensive patients based on their sensitivity to each lifestyle modification component.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.4" xml:id="_buzUxsv">| Rationale of study patients</head><p xml:id="_gXn8GW3"><s xml:id="_D7f929N">The target patients of the HERB-DH1 trial are non-medicated younger adults (30-64 years of age) with mild-to-moderate hypertension (140-159/90-99 mmHg).</s><s xml:id="_EGFBDCP">All of the major guidelines recommend that patients with mild-to-moderate hypertension receive non-pharmacological intervention starting at the time of diagnosis of hypertension before antihypertensive medication is initiated. <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b6">7,</ref><ref type="bibr" target="#b25">26</ref></s><s xml:id="_9FgQcnC"> addition, the predominant cause of systolic hypertension in the elderly is increased arterial stiffness, and we speculate that the BP reduction, especially 24-hour SBP, may take a longer time in elderly hypertensives <ref type="bibr" target="#b39">40</ref> .</s><s xml:id="_XuEZK5J">In the perspective of the DTx, younger people are generally more comfortable with the use of smartphones and thus may find it easier to use a new app than the elderly.</s><s xml:id="_8VdW3xp">We will therefore target younger adults in the early stage of hypertension to evaluate the BP-lowering effect within a relatively short period of time in this study.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.5" xml:id="_6mBAbwS">| Digital therapeutics</head><p xml:id="_RCuU9Ct"><s xml:id="_Vfh97HF">Digital therapeutics can provide evidence-based intervention to prevent, manage, or treat diseases independently or in combination with existing therapies. <ref type="bibr" target="#b15">16</ref></s><s xml:id="_6KMaVfR">For example, the randomized controlled trial of a novel DTx smartphone app, CureApp-SC ™ , demonstrated the significant clinical efficacy of the app when used in conjunction with standard-of-care (SoC) compared with SoC alone for nicotine dependence. <ref type="bibr" target="#b40">41</ref></s><s xml:id="_YaAcrWE">Today, nearly 80% of the general population in Japan use smartphones, which far exceeds the usage rate for personal computers. <ref type="bibr" target="#b41">42</ref></s><s xml:id="_xvkzt9Q">We expect that our HERB system will be a highly promising DTx to significantly lower BP for essential hypertension when used together with SoC by continuously promoting behavioral changes in users via daily use of a smartphone.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.6" xml:id="_WhDndhK">| Study limitation</head><p xml:id="_UP48S8Q"><s xml:id="_BJWA3P3">This is an open-label study because the control group will not use the application, patients will thus recognize whether they have</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><figDesc><div><p xml:id="_xPDMsP4"><s xml:id="_rMzA4gT">style modification: Step 1) input and education; Step 2) app-initiated experiments; and Step 3) self-planning and evaluation (Figure 3).</s><s xml:id="_e8tEYRb">First, in Step 1, the app provides each user a personalized educational program including lectures and advice via a virtual nurse to enhance their lifestyle modifications for the control of essential hypertension.</s><s xml:id="_FZCNn52">Next, in Step 2, the app instructs users non-pharmacological interventions, for example, reduced salt intake, exercise or smoking cessation, to lower their BP based on the knowledge and techniques given in Step 1. Finally, in Step 3, the app encourages users to create their own strategies to lower their BP by combining some of the non-pharmacological interventions learned in Step 2. Users will also be encouraged to evaluate and review the process and results of their individually devised plans.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>F</head><figDesc><div><p xml:id="_qDXvVqp"><s xml:id="_FmQ6E7X">I G U R E 1 CONSORT flowchartTA B L E 1 Follow-up assessment schedule of the trial</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><figDesc><div><p xml:id="_wBGwqme"><s xml:id="_SDtXe2D">prohibited due to their potential to affect BP: (a) antihypertensive medications except when indicated based on the ambulatory BP levels taken at 12 weeks after registration; (b) the use of application software that measures BP, stores measured BP data or aims to reduce BPs; (c) intake of any foods approved by the Consumer Affairs Agency as "food for specified health uses"; (d) use of medications or Chinese herbal medicines known to cause drug-induced hypertension (eg, non-steroidal anti-inflammatory drugs, licorice, glucocorticoid, cyclosporine, erythropoietin, oral contraceptives, and sympathomimetic agents [topical product as ophthalmic solution or ointments are excluded]); and (e) use of sodium-glucose transporter 2 inhibitors, which have been shown to lower home and ambulatory</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>1 ) 2 ) Suspected secondary hypertensions 3 ) Use of contraindicated medications 4 ) 5 )</head><label>12345</label><figDesc><div><p xml:id="_d3mhsJE"><s xml:id="_2htFQwU">Office SBP ≥180 mmHg and/or DBP ≥110 mmHg Recommended immediate medication therapy by medical history and/or comorbidities.</s><s xml:id="_hsZZS9D">Female with pregnancy or expecting 6) History of renal denervation therapy 7) Do not have or use a smartphone daily 8) Participating in ongoing clinical trials, or participated in the previous HERB pilot study 9) Relatives or cohabitant partners who have already participated in this trial 10) Judged by the investigator or clinical trial physicians to be unsuitable for participation in this trial for any other reason</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>(</head><figDesc><div><p xml:id="_FcVwR27"><s xml:id="_2PBtYVT">University Hospital Medical Information Network Clinical Trial Registry [UMIN-CTR] ID: UMIN000033311), the difference in the mean change from baseline to 16 weeks in 24-hour SBP by ABPM between the HERB system and Control groups was 7.6 mmHg, and the SD of the HERB group was 11.5 mmHg in 59 medication-naïve patients between the ages of 20 and 65.</s><s xml:id="_WUKY7WX">Thus, we set the estimated difference in the mean change in 24-hour SBP between the inter-</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><figDesc><div><p xml:id="_zhP4kDZ"><s xml:id="_HSqBmF8">HERB-DH1 pivotal study is the first clinical trial designed to evaluate the efficacy of the ICT-based, BP-lowering DTx synergistically facilitating the medically well-validated non-pharmacological interventions at the individual level in patients with essential hypertension.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_7"><head>3. 3 |</head><label>3</label><figDesc><div><p xml:id="_SkJwHuQ"><s xml:id="_hF3DeBT">Personalized intervention of HERBHERB Mobile will provide the personalized antihypertensive guidance including multiple components of the lifestyle modification interventions.</s><s xml:id="_8pW3Tah">The response to each intervention may vary according to the patient's background, because the effectiveness of each component depends not only on the pressor mechanism of each individual patient, but also on the patient's motivation and preference for each intervention.</s><s xml:id="_3RsBxjw">However, previous non-pharmacological intervention trials have been conducted in the same standardized manner without considering the motivations and preferences of in-</s></p></div></figDesc></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_0"><p xml:id="_BFQJCmy"><s xml:id="_qh2kQUQ">17517176, 2020, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/jch.13993,</s><s xml:id="_zhe3eC9">Wiley Online Library on [12/03/2025].</s><s xml:id="_xacTayA">See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions)</s><s xml:id="_Z5qawa5">on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License</s></p></note>
		</body>
		<back>

			<div type="funding">
<div xml:id="_rKcpe2w"><p xml:id="_aFH5ySH"><s xml:id="_B4upJJX">supported by <rs type="funder">CureApp Inc. CureApp Inc</rs>. provided funding and contributed to the development of the HERB system and the design of the trial.</s></p></div>
			</div>
			<listOrg type="funding">
			</listOrg>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_v7d4h48"><p xml:id="_rsdgqey"><s xml:id="_XvUg4tW">| 1721 KARIO et Al.</s></p><p xml:id="_3vt3G8j"><s xml:id="_ATgvzY7">been allocated to the application group or control group.</s><s xml:id="_jjxd9P6">In addition, both groups will equally receive doctors' instructions based on JSH 2019 Guidelines, 1 in regard to non-pharmacological interventions in their clinical practice.</s><s xml:id="_Hrn6EKG">Such "face-to-face" instruction from the doctors may overwhelm the BP-lowering effect of the application over the relatively short time period of the study.</s><s xml:id="_fqHerrf">Moreover, the TASMINH4, an unmasked randomized controlled trial, demonstrated that self-BP monitoring, with or without tele-monitoring, to titrate antihypertensive medication in individuals with poorly controlled blood pressure, leads to significantly lower BP than titration guided by clinic readings. <ref type="bibr" target="#b42">43</ref></s><s xml:id="_jtU5UV4">In the settings of our study, patients in both the groups will manage their BP by self-monitoring although tele-monitoring is only applied for the app group.</s><s xml:id="_GtRN4h4">Therefore, a certain amount of BP-lowering effect may occur in both these groups by just conducting HBPM and by doctors' instruction based on JSH2019 Guidelines.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4" xml:id="_rpqfcrZ">| CON CLUS I ON S AND PER S PEC TIVE S</head><p xml:id="_S7ERb38"><s xml:id="_9jCmJSe">This trial will allow us to verify the hypothesis that HERB Mobile, which is treatment using a smartphone application, is effective in reducing BP and also has no harm in the management of hypertension.</s><s xml:id="_sbeJzzY">If the efficacy is validated, this will be a first step toward the practical use in application-based personalized medicine for the management of hypertension.</s><s xml:id="_wuhSKaR">We started this study in December of 2019, and the trial results will be disseminated in early 2021.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_MYfsu6B">ACK N OWLED G M ENT</head><p xml:id="_Wm6v3mk"><s xml:id="_EN4NqHq">We would like to express our gratitude to all the trial participants and staff.</s><s xml:id="_dsXyWb6">We also thank Mr. Hiroshi Mamada, Ms. Tomoko Shiga, Ms. Chiharu Saito, and Ms. Tomoko Morimoto for their study coordination and data management.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_j5YEAxR">CO N FLI C T O F I NTE R E S</head></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main" xml:id="_CFgfVAK">The Japanese Society of Hypertension Guidelines for the management of hypertension (JSH 2019)</title>
		<author>
			<persName><forename type="first">S</forename><surname>Umemura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Arima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Arima</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41440-019-0284-9</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_QqvNd6x">Hypertens Res</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1235" to="1481" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Umemura S, Arima H, Arima S, et al. The Japanese Society of Hypertension Guidelines for the management of hypertension (JSH 2019). Hypertens Res. 2019;42(9):1235-1481.</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main" xml:id="_JDPTMPY">Blood pressure categories and long-term risk of cardiovascular disease according to age group in Japanese men and women</title>
		<author>
			<persName><forename type="first">A</forename><surname>Fujiyoshi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ohkubo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Miura</surname></persName>
		</author>
		<idno type="DOI">10.1038/hr.2012.87</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_YRJ8QHT">Hypertens Res</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="947" to="953" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Fujiyoshi A, Ohkubo T, Miura K, et al. Blood pressure categories and long-term risk of cardiovascular disease according to age group in Japanese men and women. Hypertens Res. 2012;35(9):947-953.</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main" xml:id="_yTtRZjS">Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Law</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Morris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Wald</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmj.b1665</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_HuhbS5s">BMJ</title>
		<imprint>
			<biblScope unit="volume">338</biblScope>
			<biblScope unit="page">1665</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main" xml:id="_Kr8aD6U">Blood Pressure Lowering Treatment Trialists C. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data</title>
		<author>
			<orgName type="collaboration">Blood Pressure Lowering Treatment Trialists&apos; Collaboration</orgName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_2UvKeP5">Lancet</title>
		<imprint>
			<biblScope unit="volume">384</biblScope>
			<biblScope unit="page" from="591" to="598" />
			<date type="published" when="2014">2014. 9943</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Blood Pressure Lowering Treatment Trialists&apos; Collaboration. Blood Pressure Lowering Treatment Trialists C. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individ- ual patient data. Lancet. 2014;384(9943):591-598.</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main" xml:id="_3zjNj8t">Global impact of 2017 American Heart Association/ American College of Cardiology Hypertension Guidelines: a perspective from Japan</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kario</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_dW4G7ry">Circulation</title>
		<imprint>
			<biblScope unit="volume">137</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="543" to="545" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kario K. Global impact of 2017 American Heart Association/ American College of Cardiology Hypertension Guidelines: a per- spective from Japan. Circulation. 2018;137(6):543-545.</note>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<title level="m" type="main" xml:id="_M8sg9m4">Essential Manual on Perfect 24-hour Blood Pressure Management from Morning to Nocturnal Hypertension: Up-to-date for Anticipation Medicine</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kario</surname></persName>
		</author>
		<idno type="DOI">10.1002/9781119799412</idno>
		<imprint>
			<date type="published" when="2018">2018</date>
			<publisher>Wiley</publisher>
			<biblScope unit="page" from="1" to="309" />
			<pubPlace>Tokyo, Japan</pubPlace>
		</imprint>
	</monogr>
	<note type="raw_reference">Kario K. Essential Manual on Perfect 24-hour Blood Pressure Management from Morning to Nocturnal Hypertension: Up-to-date for Anticipation Medicine. Tokyo, Japan: Wiley; 2018:1-309.</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main" xml:id="_VBmznsb">ACC/AHA/AAPA/ ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">K</forename><surname>Whelton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Carey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">S</forename><surname>Aronow</surname></persName>
		</author>
		<idno type="DOI">10.1161/hyp.0000000000000080</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_W7zMZRT">Circulation</title>
		<imprint>
			<biblScope unit="volume">138</biblScope>
			<biblScope unit="issue">17</biblScope>
			<biblScope unit="page" from="426" to="e483" />
			<date type="published" when="2017">2017. 2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018;138(17):e426-e483.</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main" xml:id="_gWeKKYf">Could 130/80 mm Hg be adopted as the diagnostic threshold and management goal of hypertension in consideration of the characteristics of Asian populations?</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kario</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Wang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_jdf6wRD">Hypertension</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="979" to="984" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kario K, Wang JG. Could 130/80 mm Hg be adopted as the diag- nostic threshold and management goal of hypertension in consid- eration of the characteristics of Asian populations? Hypertension. 2018;71(6):979-984.</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main" xml:id="_jUYBkpR">The emerging field of mobile health</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Steinhubl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">D</forename><surname>Muse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Topol</surname></persName>
		</author>
		<idno type="DOI">10.1126/scitranslmed.aaa3487</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Nb8gfNJ">Sci Transl Med</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">283</biblScope>
			<biblScope unit="page" from="283" to="283" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Steinhubl SR, Muse ED, Topol EJ. The emerging field of mobile health. Sci Transl Med. 2015;7(283):283rv3.</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main" xml:id="_kSyeGMk">A decade of digital medicine innovation</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Topol</surname></persName>
		</author>
		<idno type="DOI">10.1126/scitranslmed.aaw7610</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_22FxFC8">Sci Transl Med</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">498</biblScope>
			<biblScope unit="page">7610</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Topol EJ. A decade of digital medicine innovation. Sci Transl Med. 2019;11(498):eaaw7610.</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main" xml:id="_8uY4VMG">Impact of a novel smartphone app (CureApp smoking cessation) on nicotine dependence: prospective single-arm interventional pilot study</title>
		<author>
			<persName><forename type="first">K</forename><surname>Masaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Tateno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Kameyama</surname></persName>
		</author>
		<idno type="DOI">10.2196/12694</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_rQMACc4">JMIR Mhealth Uhealth</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page">12694</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Masaki K, Tateno H, Kameyama N, et al. Impact of a novel smart- phone app (CureApp smoking cessation) on nicotine dependence: prospective single-arm interventional pilot study. JMIR Mhealth Uhealth. 2019;7(2):e12694.</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main" xml:id="_TkbpXPH">A novel smoking cessation smartphone app integrated with a mobile carbon monoxide checker for smoking cessation treatment: protocol for a randomized controlled trial</title>
		<author>
			<persName><forename type="first">A</forename><surname>Nomura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Tateno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Masaki</surname></persName>
		</author>
		<idno type="DOI">10.2196/12252</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_HVgZtmz">JMIR Res Protoc</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">e12252</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Nomura A, Tateno H, Masaki K, et al. A novel smoking cessation smartphone app integrated with a mobile carbon monoxide checker for smoking cessation treatment: protocol for a randomized con- trolled trial. JMIR Res Protoc. 2019;8:e12252.</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main" xml:id="_24kNcUN">Internet-delivered treatment for substance abuse: a multisite randomized controlled trial</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">N</forename><surname>Campbell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">V</forename><surname>Nunes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Matthews</surname></persName>
		</author>
		<idno type="DOI">10.1176/appi.ajp.2014.13081055</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_rmBQBv3">Am J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">171</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="683" to="690" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Campbell AN, Nunes EV, Matthews AG, et al. Internet-delivered treatment for substance abuse: a multisite randomized controlled trial. Am J Psychiatry. 2014;171(6):683-690.</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main" xml:id="_3dEzqmV">A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Koliins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Deloss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Canadas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_4Anh7dM">Lancet Digital Health</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="168" to="E178" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Koliins SH, DeLoss DJ, Canadas E, et al. A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial. Lancet Digital Health. 2020;2(4):E168 -E178.</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main" xml:id="_6Xp9duq">Effect of intensive salt-restriction education on clinic, home, and ambulatory blood pressure levels in treated hypertensive patients during a 3-month education period</title>
		<author>
			<persName><forename type="first">M</forename><surname>Nakano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Eguchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Sato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Onoguchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hoshide</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kario</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_uCHqAKN">J Clin Hypertens</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="385" to="392" />
			<date type="published" when="2016">2016</date>
			<pubPlace>Greenwich)</pubPlace>
		</imprint>
	</monogr>
	<note type="raw_reference">Nakano M, Eguchi K, Sato T, Onoguchi A, Hoshide S, Kario K. Effect of intensive salt-restriction education on clinic, home, and ambulatory blood pressure levels in treated hypertensive patients during a 3-month education period. J Clin Hypertens (Greenwich). 2016;18(5):385-392.</note>
</biblStruct>

<biblStruct xml:id="b15">
	<monogr>
		<idno type="DOI">10.1080/23257962.2020.1813559</idno>
		<ptr target="https://dtxalliance.org" />
		<title level="m" xml:id="_gHMCXs2">Digital therapeutics alliance</title>
		<imprint>
			<date type="published" when="2020-03-26">26 March, 2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Digital therapeutics alliance. https://dtxal liance.org. Accessed 26 March, 2020.</note>
</biblStruct>

<biblStruct xml:id="b16">
	<monogr>
		<title level="m" type="main" xml:id="_33wJnZH">Designing for Behavior Change</title>
		<author>
			<persName><forename type="first">S</forename><surname>Wendel</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2014">2014</date>
			<publisher>O&apos;Reilly Media, Inc</publisher>
			<pubPlace>USA</pubPlace>
		</imprint>
	</monogr>
	<note type="raw_reference">Wendel S. Designing for Behavior Change. USA: O&apos;Reilly Media, Inc.; 2014.</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main" xml:id="_pXw66eY">24-hour blood pressure-lowering effect of an SGLT-2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized placebo-controlled SACRA study</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kario</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Okada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kato</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_CvJ6Q9v">Circulation</title>
		<imprint>
			<biblScope unit="volume">139</biblScope>
			<biblScope unit="issue">18</biblScope>
			<biblScope unit="page" from="2089" to="2097" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kario K, Okada K, Kato M, et al. 24-hour blood pressure-lowering effect of an SGLT-2 inhibitor in patients with diabetes and uncon- trolled nocturnal hypertension: results from the randomized place- bo-controlled SACRA study. Circulation. 2018;139(18):2089-2097.</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main" xml:id="_gYMRGEg">Effect of canagliflozin on nocturnal home blood pressure in Japanese patients with type 2 diabetes mellitus: The SHIFT-J study</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kario</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hoshide</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Okawara</surname></persName>
		</author>
		<idno type="DOI">10.1111/jch.13367</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_q4XhYDR">J Clin Hypertens</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1527" to="1535" />
			<date type="published" when="2018">2018</date>
			<pubPlace>Greenwich)</pubPlace>
		</imprint>
	</monogr>
	<note type="raw_reference">Kario K, Hoshide S, Okawara Y, et al. Effect of canagliflozin on nocturnal home blood pressure in Japanese patients with type 2 diabetes mellitus: The SHIFT-J study. J Clin Hypertens (Greenwich). 2018;20(10):1527-1535.</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main" xml:id="_2sTfdPH">Validation of the TM-2441 ambulatory blood pressure measurement device according to the ISO 81060-2: 2013 standard</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kario</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hoshide</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Saito</surname></persName>
		</author>
		<idno type="DOI">10.1097/mbp.0000000000000357</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_awckNRw">Blood Press Monit</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="38" to="41" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kario K, Hoshide S, Saito K, et al. Validation of the TM-2441 am- bulatory blood pressure measurement device according to the ISO 81060-2: 2013 standard. Blood Press Monit. 2019;24(1):38-41.</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main" xml:id="_A6UC6aJ">Guidelines for the clinical use of 24 hour ambulatory blood pressure monitoring (ABPM) (JCS 2010): -digest version</title>
		<author>
			<orgName type="collaboration">JCS Joint Working Group</orgName>
		</author>
		<idno type="DOI">10.1253/circj.cj-88-0020</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_9thQFe6">Circ J</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="508" to="519" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">JCS Joint Working Group. Guidelines for the clinical use of 24 hour ambulatory blood pressure monitoring (ABPM) (JCS 2010): -digest version. Circ J. 2012;76(2):508-519.</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main" xml:id="_BvHGvdp">Current status of ambulatory blood pressure monitoring in Asian countries: a report from the HOPE Asia Network</title>
		<author>
			<persName><forename type="first">J</forename><surname>Shin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kario</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">C</forename><surname>Chia</surname></persName>
		</author>
		<idno type="DOI">10.1111/jch.13724</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_e8Qh5v5">J Clin Hypertens</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="384" to="390" />
			<date type="published" when="2020">2020</date>
			<pubPlace>Greenwich)</pubPlace>
		</imprint>
	</monogr>
	<note type="raw_reference">Shin J, Kario K, Chia YC, et al. Current status of ambulatory blood pressure monitoring in Asian countries: a report from the HOPE Asia Network. J Clin Hypertens (Greenwich). 2020;22(3):384-390.</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main" xml:id="_N6udym7">Expert panel consensus recommendations for ambulatory blood pressure monitoring in Asia: the HOPE Asia Network</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kario</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Shin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Chen</surname></persName>
		</author>
		<idno type="DOI">10.1111/jch.13652</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_9YfhJcy">J Clin Hypertens</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1250" to="1283" />
			<date type="published" when="2019">2019</date>
			<pubPlace>Greenwich)</pubPlace>
		</imprint>
	</monogr>
	<note type="raw_reference">Kario K, Shin J, Chen CH, et al. Expert panel consensus recommen- dations for ambulatory blood pressure monitoring in Asia: the HOPE Asia Network. J Clin Hypertens (Greenwich). 2019;21(9):1250-1283.</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main" xml:id="_hAXkffF">Expert panel consensus recommendations for home blood pressure monitoring in Asia: the Hope Asia Network</title>
		<author>
			<persName><forename type="first">S</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Buranakitjaroen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Ys9uYVb">J Hum Hypertens</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="249" to="258" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Park S, Buranakitjaroen P, Chen CH, et al. Expert panel consensus recommendations for home blood pressure monitoring in Asia: the Hope Asia Network. J Hum Hypertens. 2018;32(4):249-258.</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main" xml:id="_AQK6N3x">Guidance on home blood pressure monitoring: a statement of the HOPE Asia Network</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kario</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Buranakitjaroen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_RcmBPVg">J Clin Hypertens</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="456" to="461" />
			<date type="published" when="2018">2018</date>
			<pubPlace>Greenwich)</pubPlace>
		</imprint>
	</monogr>
	<note type="raw_reference">Kario K, Park S, Buranakitjaroen P, et al. Guidance on home blood pressure monitoring: a statement of the HOPE Asia Network. J Clin Hypertens (Greenwich). 2018;20(3):456-461.</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main" xml:id="_Mszqgwu">ESC/ESH guidelines for the management of arterial hypertension</title>
		<author>
			<persName><forename type="first">B</forename><surname>Williams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Mancia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Spiering</surname></persName>
		</author>
		<idno type="DOI">10.1093/eurheartj/ehy439</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_H5aRKtG">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="issue">33</biblScope>
			<biblScope unit="page" from="3021" to="3104" />
			<date type="published" when="2018">2018. 2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guide- lines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104.</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main" xml:id="_8XPyRhY">Emergence of home blood pressure-guided management of hypertension based on global evidence</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kario</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Shimbo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hoshide</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_zgQRY5b">Hypertension</title>
		<imprint>
			<biblScope unit="volume">74</biblScope>
			<biblScope unit="page" from="229" to="236" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kario K, Shimbo D, Hoshide S, et al. Emergence of home blood pressure-guided management of hypertension based on global evi- dence. Hypertension. 2019;74:229-236.</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main" xml:id="_7XNM8ED">Blood pressure measurement and treatment decisions</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kario</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Thijs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Staessen</surname></persName>
		</author>
		<idno type="DOI">10.1161/circresaha.118.313219</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_c5MRfaR">Circ Res</title>
		<imprint>
			<biblScope unit="volume">124</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="990" to="1008" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kario K, Thijs L, Staessen JA. Blood pressure measurement and treatment decisions. Circ Res. 2019;124(7):990-1008.</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main" xml:id="_r695NXD">Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial</title>
		<author>
			<persName><forename type="first">M</forename><surname>Böhm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kario</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Kandzari</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_W54KCv5">Lancet</title>
		<imprint>
			<biblScope unit="volume">395</biblScope>
			<biblScope unit="issue">10234</biblScope>
			<biblScope unit="page" from="1444" to="1451" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sh- am-controlled trial. Lancet. 2020;395(10234):1444-1451.</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main" xml:id="_FuaRQ8e">Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Kandzari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bohm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Mahfoud</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_EpcR6VM">Lancet</title>
		<imprint>
			<biblScope unit="volume">391</biblScope>
			<biblScope unit="issue">10137</biblScope>
			<biblScope unit="page" from="2346" to="2355" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kandzari DE, Bohm M, Mahfoud F, et al. Effect of renal dener- vation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391(10137):2346-2355.</note>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main" xml:id="_Hc6eT3s">Impact of introducing catheter-based renal denervation into Japan for hypertension management: estimation of number of target patients and clinical relevance of ambulatory blood pressure reduction</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kario</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Okura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Okawara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Tomitani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ikemoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hoshide</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_qWpDcQA">Curr Hypertens Rev</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="156" to="163" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kario K, Okura A, Okawara Y, Tomitani N, Ikemoto T, Hoshide S. Impact of introducing catheter-based renal denervation into Japan for hypertension management: estimation of number of target pa- tients and clinical relevance of ambulatory blood pressure reduc- tion. Curr Hypertens Rev. 2016;12(2):156-163.</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main" xml:id="_gyRcmZz">Effect of modest salt reduction on blood pressure: a meta-analysis of randomized trials. Implications for public health</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Macgregor</surname></persName>
		</author>
		<idno type="DOI">10.1038/sj.jhh.1001459</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_k9UVF86">J Hum Hypertens</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="761" to="770" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note type="raw_reference">He FJ, MacGregor GA. Effect of modest salt reduction on blood pressure: a meta-analysis of randomized trials. Implications for pub- lic health. J Hum Hypertens. 2002;16(11):761-770.</note>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main" xml:id="_BZdJq4E">Long-term effects of weight-reducing diets in people with hypertension</title>
		<author>
			<persName><forename type="first">T</forename><surname>Semlitsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Jeitler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Berghold</surname></persName>
		</author>
		<idno type="DOI">10.1002/14651858.cd008274.pub3</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_QY25T8k">Cochrane Database Syst Rev</title>
		<imprint>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page">8274</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Semlitsch T, Jeitler K, Berghold A, et al. Long-term effects of weight-reducing diets in people with hypertension. Cochrane Database Syst Rev. 2016;(3):CD008274.</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main" xml:id="_fHGT89k">Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">O</forename><surname>Dickinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Mason</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Nicolson</surname></persName>
		</author>
		<idno type="DOI">10.1097/01.hjh.0000199800.72563.26</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_CGhtqUy">J Hypertens</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="215" to="233" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Dickinson HO, Mason JM, Nicolson DJ, et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens. 2006;24(2):215-233.</note>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main" xml:id="_MB4c3xe">Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials</title>
		<author>
			<persName><forename type="first">X</forename><surname>Xin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Frontini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">G</forename><surname>Ogden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">I</forename><surname>Motsamai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">K</forename><surname>Whelton</surname></persName>
		</author>
		<idno type="DOI">10.1161/hy1101.093424</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_BNubk85">Hypertension</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1112" to="1117" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Xin X, He J, Frontini MG, Ogden LG, Motsamai OI, Whelton PK. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2001;38(5):1112-1117.</note>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main" xml:id="_z69hvPF">Salt intake and risk of disaster hypertension among evacuees in a shelter after the Great East Japan earthquake</title>
		<author>
			<persName><forename type="first">S</forename><surname>Hoshide</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Nishizawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Okawara</surname></persName>
		</author>
		<idno type="DOI">10.1161/hypertensionaha.119.12943</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Xywyjmk">Hypertension</title>
		<imprint>
			<biblScope unit="volume">74</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="564" to="571" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hoshide S, Nishizawa M, Okawara Y, et al. Salt intake and risk of disaster hypertension among evacuees in a shelter after the Great East Japan earthquake. Hypertension. 2019;74(3):564-571.</note>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main" xml:id="_wnqjXMT">Sleep duration and quality: impact on lifestyle behaviors and cardiometabolic health: a scientific statement from the American Heart Association</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>St-Onge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Grandner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Brown</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_kuwvUsT">Circulation</title>
		<imprint>
			<biblScope unit="volume">134</biblScope>
			<biblScope unit="issue">18</biblScope>
			<biblScope unit="page" from="367" to="e386" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">St-Onge MP, Grandner MA, Brown D, et al. Sleep duration and qual- ity: impact on lifestyle behaviors and cardiometabolic health: a sci- entific statement from the American Heart Association. Circulation. 2016;134(18):e367-e386.</note>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main" xml:id="_NttaX7v">Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Sacks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">P</forename><surname>Svetkey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">M</forename><surname>Vollmer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Gx8DAME">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">344</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="3" to="10" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pres- sure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;344(1):3-10.</note>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main" xml:id="_SupGbCv">Predictors and mediators of successful long-term withdrawal from antihypertensive medications</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Espeland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Cooperative</forename><forename type="middle">Research</forename><surname>Tone</surname></persName>
		</author>
		<author>
			<persName><surname>Group</surname></persName>
		</author>
		<idno type="DOI">10.1001/archfami.8.3.228</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_pszCNns">Arch Fam Med</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="228" to="236" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Espeland MA, TONE Cooperative Research Group. Predictors and mediators of successful long-term withdrawal from antihyperten- sive medications. Arch Fam Med. 1999;8:228-236.</note>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main" xml:id="_xe4Rs3F">Systemic hemodynamic atherothrombotic syndrome (SHATS) -Coupling vascular disease and blood pressure variability: Proposed concept from pulse of Asia</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kario</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Chirinos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Townsend</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.pcad.2019.11.002</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_rWbmEpF">Prog Cardiovasc Dis</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="22" to="32" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kario K, Chirinos JA, Townsend RR, et al. Systemic hemodynamic atherothrombotic syndrome (SHATS) -Coupling vascular disease and blood pressure variability: Proposed concept from pulse of Asia. Prog Cardiovasc Dis. 2020;63(1):22-32.</note>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main" xml:id="_ctvPMFB">A randomized controlled trial of a smoking cessation smartphone application with a carbon monoxide checker</title>
		<author>
			<persName><forename type="first">K</forename><surname>Masaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Tateno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nomura</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41746-020-0243-5</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_UyGdhaT">NPJ Digit Med</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">35</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Masaki K, Tateno H, Nomura A, et al. A randomized controlled trial of a smoking cessation smartphone application with a carbon mon- oxide checker. NPJ Digit Med. 2020;3:35.</note>
</biblStruct>

<biblStruct xml:id="b41">
	<monogr>
		<title level="m" type="main" xml:id="_mXeFMTv">Information and communications in Japan: white Paper</title>
		<idno type="DOI">10.1163/2210-7975_hrd-1198-0068</idno>
		<ptr target="https://www.soumu.go.jp/johotsusintokei/whitepaper/eng/WP2019/2019-index.html" />
		<imprint>
			<date type="published" when="2019-03-25">2019. 25 March, 2020</date>
			<publisher>Ministry of Internal Affairs and Communications Japan</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Ministry of Internal Affairs and Communications Japan. Information and communications in Japan: white Paper 2019. https://www. soumu.go.jp/johot susin tokei/ white paper/ eng/WP201 9/2019- index.html. Accessed 25 March, 2020.</note>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main" xml:id="_kyVf4wH">Efficacy of self-monitored blood pressure, with or without telemonitoring, for titration of antihypertensive medication (TASMINH4): an unmasked randomised controlled trial</title>
		<author>
			<persName><forename type="first">R</forename><surname>Mcmanus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Franssen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_EZrwnn2">Lancet</title>
		<imprint>
			<biblScope unit="volume">391</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="949" to="959" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">McManus R, Mant J, Franssen M, et al. Efficacy of self-monitored blood pressure, with or without telemonitoring, for titration of an- tihypertensive medication (TASMINH4): an unmasked randomised controlled trial. Lancet. 2018;391(3):949-959.</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
